Specialty code 183500000X · Roseville, CA
NPI
1164998480
Since 2018
Specialty
Specialty code 183500000X
Code 183500000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
1600 Eureka Rd
Roseville, CA, 95661
Phone (916) 784-4000
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$14.5M
1,543 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Christina L Bi prescribed most often to Medicare patients was Abiraterone Acetate, with 562 prescriptions and refills. In total Christina L Bi wrote 1,543 Medicare prescriptions that cost $14.5M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-08-10.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Abiraterone Acetate Generic | 562 | 565 | 117 | $82K |
| Ibrance Palbociclib | 160 | 160 | 32 | $2.5M |
| Tagrisso Osimertinib Mesylate | 147 | 147 | 27 | $2.4M |
| Verzenio Abemaciclib | 133 | 133 | 19 | $2.2M |
| Brukinsa Zanubrutinib | 89 | 89 | 17 | $1.0M |
| Imatinib Mesylate Generic | 58 | 58 | 11 | $2,898 |
| Cabometyx Cabozantinib S-Malate | 44 | 44 | Under 11 | $825K |
| Kisqali Ribociclib Succinate | 36 | 36 | Under 11 | $587K |
| Lynparza Olaparib | 33 | 33 | Under 11 | $452K |
| Zejula Niraparib Tosylate | 32 | 32 | Under 11 | $531K |
| Tafinlar Dabrafenib Mesylate | 27 | 30 | Under 11 | $320K |
| Alecensa Alectinib Hcl | 21 | 24 | Under 11 | $421K |
| Calquence Acalabrutinib Maleate | 20 | 20 | Under 11 | $151K |
| Sprycel Dasatinib | 17 | 17 | Under 11 | $308K |
| Lenvima Lenvatinib Mesylate | 16 | 16 | Under 11 | $335K |
Brand drugs: 903 claims; generic drugs: 640 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Christina L Bi were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.